If you or a loved one took Ozempic, Wegovy, or another GLP-1 receptor agonist and suffered serious side effects — particularly gastroparesis, intestinal blockages, or gallbladder problems — you may be eligible to file a lawsuit and recover financial compensation. Thousands of claims have already been consolidated into multidistrict litigation (MDL No. 3094) in the Eastern District of Pennsylvania, and attorneys across the country are actively reviewing cases from people who experienced severe gastrointestinal harm after using these medications. For families dealing with dementia care, where medication management is already fraught with complexity, understanding these legal options matters because cognitive decline can make it harder to recognize adverse drug reactions or advocate for oneself. This is not theoretical.
Consider a 71-year-old woman with early-stage Alzheimer’s whose physician prescribed Ozempic for type 2 diabetes management. Within months, she developed severe gastroparesis — a condition where the stomach essentially stops emptying — leading to hospitalization, a feeding tube, and a sharp cognitive decline accelerated by malnutrition and dehydration. Her family had no idea the medication could cause such harm because, they allege, the drug’s manufacturer Novo Nordisk failed to adequately warn about these risks. Cases like hers are exactly what this litigation targets. This article covers who qualifies, what the legal process looks like, how dementia and cognitive impairment factor into filing a claim, the types of compensation available, and what families should do right now if they suspect harm.
Table of Contents
- Who Qualifies for Ozempic Compensation and What Injuries Count?
- How the Ozempic Lawsuits Work and What Novo Nordisk Is Accused Of
- Why Dementia Patients Face Unique Risks with GLP-1 Medications
- Types of Compensation Available and How Settlements Are Structured
- Common Obstacles and What Can Derail a Claim
- Steps Families Should Take Right Now
- What to Expect as the Litigation Moves Forward
- Conclusion
- Frequently Asked Questions
Who Qualifies for Ozempic Compensation and What Injuries Count?
Not everyone who took ozempic or a similar GLP-1 drug has a viable legal claim. The lawsuits center on specific serious injuries that plaintiffs allege were not adequately disclosed by manufacturers. The primary injuries driving litigation include gastroparesis (stomach paralysis), bowel obstruction, ileus, pancreatitis, gallbladder disease requiring surgical removal, and in some cases, aspiration during anesthesia because the drug delayed stomach emptying without the patient or surgeon being warned. If your experience was limited to mild nausea or temporary digestive upset — common and well-documented side effects — that alone is unlikely to support a lawsuit. The distinction matters. Someone who spent three days in the hospital with a confirmed bowel obstruction after six months on Wegovy has a fundamentally different case than someone who felt queasy for a week after starting treatment.
Attorneys evaluating these claims typically look for documented medical records showing a diagnosed injury, evidence the person was taking a GLP-1 receptor agonist at or near the time the injury occurred, and proof that the prescribing information did not adequately warn of the specific risk. The drugs currently implicated include semaglutide (sold as Ozempic and Wegovy), liraglutide (Victoza and Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro and Zepbound). For families managing dementia, there is an additional wrinkle. A person with moderate to advanced cognitive impairment may not be able to articulate symptoms like severe abdominal pain, may not connect their suffering to a medication, or may have medical records that are complicated by multiple providers and polypharmacy. This does not disqualify them from a claim, but it does mean a family member or legal guardian may need to act on their behalf. Courts routinely allow representatives to file lawsuits for incapacitated individuals through mechanisms like guardianship or power of attorney.
How the Ozempic Lawsuits Work and What Novo Nordisk Is Accused Of
The core allegation in the GLP-1 litigation is a failure to warn. Plaintiffs are not arguing that Ozempic should never have been sold — they are arguing that manufacturers knew or should have known about the risk of severe gastrointestinal injuries and failed to include adequate warnings on the drug’s label. Internal documents, scientific literature, and FDA adverse event reports form the backbone of these claims. In 2023, the FDA did update labeling for some GLP-1 drugs to include intestinal obstruction, but plaintiffs argue this came too late and still does not go far enough regarding gastroparesis. The cases have been consolidated into a multidistrict litigation, which means that while each plaintiff retains their own individual claim, pretrial proceedings like discovery and motions are handled by a single federal judge to avoid duplicating work across hundreds of courtrooms. Judge Gene Pratter is overseeing MDL 3094 in Philadelphia.
Bellwether trials — test cases selected to gauge how juries respond to the evidence — are being prepared, and their outcomes will heavily influence whether Novo Nordisk and Eli Lilly choose to negotiate a global settlement or fight each case individually. However, if you filed a claim hoping for a quick payout, that is unlikely. MDLs are notoriously slow. The litigation is still in relatively early stages as of early 2026, and even optimistic projections suggest bellwether trials will not conclude before late 2026 or 2027. If a settlement fund is eventually established, it could take additional years before payments are distributed. For elderly claimants with dementia, this timeline presents a real concern — some may not survive to see resolution. Attorneys experienced in mass tort cases can sometimes negotiate expedited processing for plaintiffs with terminal conditions or advanced age, but this is not guaranteed.
Why Dementia Patients Face Unique Risks with GLP-1 Medications
The intersection of GLP-1 drugs and cognitive impairment deserves specific attention because dementia patients are disproportionately vulnerable to the kinds of harm at the center of these lawsuits. Many people with Alzheimer’s or other dementias also have type 2 diabetes — the overlap is significant, with research suggesting diabetes increases dementia risk by 60 to 70 percent. This means GLP-1 drugs are commonly prescribed in the very population least equipped to monitor themselves for dangerous side effects. A person with moderate dementia may not report abdominal pain accurately. They may not connect weeks of worsening constipation and vomiting to their medication. Caregivers and family members — already stretched thin — may attribute new gastrointestinal symptoms to aging, diet changes, or the dementia itself.
One family in a reported case described how their father, diagnosed with vascular dementia and prescribed Ozempic for diabetes, suffered from what turned out to be a bowel obstruction for nearly two weeks before anyone realized the severity. By the time he reached the emergency room, he required emergency surgery. His family alleges the drug’s label gave no meaningful warning about this possibility. This pattern — delayed recognition of drug-related harm in cognitively impaired patients — is a recurring theme. It also means that the window for connecting the injury to the medication can be longer and messier in medical records, which is why preserving documentation is critical. If you are a caregiver and your loved one experienced a serious gastrointestinal event while on any GLP-1 medication, request complete medical records now, even if you are not sure you want to pursue legal action. Records are easier to obtain while they are recent, and hospitals are only required to retain them for a limited number of years depending on state law.
Types of Compensation Available and How Settlements Are Structured
If the Ozempic litigation results in settlements or jury verdicts, plaintiffs could recover several categories of compensation. Economic damages cover quantifiable losses: medical bills for hospitalizations and surgeries, the cost of ongoing treatment for conditions like chronic gastroparesis, lost wages if the person was still working, and out-of-pocket expenses for things like home health aides needed during recovery. Non-economic damages cover pain and suffering, loss of quality of life, and emotional distress. In cases where a loved one died as a result of their injuries, wrongful death damages may also apply. The tradeoff families should understand is the difference between joining a mass settlement and pursuing an individual lawsuit. In a mass settlement — which is the most likely outcome if the MDL succeeds — each claimant receives a payment from a common fund, with amounts tiered based on injury severity, duration of drug use, strength of medical evidence, and other factors.
The advantage is efficiency and certainty. The disadvantage is that individual payments are almost always lower than what a standalone trial verdict might yield. By contrast, opting out of a settlement to pursue your own trial preserves the possibility of a larger award, but carries the risk of losing entirely and recovering nothing, along with years of additional litigation. For families of dementia patients, the certainty and speed of a settlement is usually the more practical choice. It is worth noting that most attorneys handling these cases work on contingency, meaning they charge no upfront fees and instead take a percentage — typically 33 to 40 percent — of any recovery. This makes legal action accessible regardless of financial resources, but families should clarify the fee structure in writing before signing any agreement.
Common Obstacles and What Can Derail a Claim
The most frequent reason a potential Ozempic claim falls apart is insufficient medical documentation. If there is no clear record showing the patient was prescribed a GLP-1 drug and no diagnosis of a qualifying injury in the medical records, proving causation becomes extraordinarily difficult. This is especially problematic for dementia patients who may have seen multiple providers, been prescribed medications by different doctors, or had records scattered across nursing facilities, hospitals, and primary care offices. Another obstacle is the statute of limitations. Every state has a deadline for filing a personal injury lawsuit, typically ranging from one to six years depending on the jurisdiction and when the injury was discovered. Some states apply a “discovery rule,” meaning the clock starts when the plaintiff knew or should have known the injury was caused by the drug, rather than when the injury first occurred.
For someone with dementia, determining when they “should have known” is legally complex. Courts may toll (pause) the statute of limitations for individuals who are mentally incapacitated, but this is not automatic — it usually requires a legal filing to establish. A third limitation worth understanding: these lawsuits only target the drug manufacturers. If your complaint is that a doctor should have recognized the side effects sooner or should not have prescribed the drug given a patient’s cognitive status, that is a medical malpractice claim — a separate legal action with its own requirements, including in most states an expert medical affidavit. Some families may have both a product liability claim against the manufacturer and a malpractice claim against a provider. These are not mutually exclusive, but they proceed on different tracks.
Steps Families Should Take Right Now
If you believe a loved one with dementia was harmed by Ozempic or another GLP-1 drug, the most productive immediate step is to gather and organize medical records. Request pharmacy records showing exactly which medications were dispensed and when, hospital and emergency room records for any gastrointestinal events, and notes from the prescribing physician. Create a simple timeline connecting drug use to symptoms and hospitalizations. This documentation package is exactly what an attorney needs to evaluate whether a case is viable.
Next, consult with a mass tort attorney — not a general practice lawyer. Look for firms that specifically list GLP-1 or Ozempic litigation on their practice areas, and verify they are actually filing cases in MDL 3094 rather than simply collecting leads to sell to other firms. A legitimate attorney will review your case at no cost and explain honestly whether the claim has merit. Be wary of any firm that guarantees a specific dollar amount or pressures you to sign immediately.
What to Expect as the Litigation Moves Forward
The GLP-1 litigation is shaping up to be one of the larger mass tort proceedings in recent years, with some legal analysts comparing its trajectory to previous pharmaceutical MDLs like those involving Vioxx or transvaginal mesh. The bellwether trial selections and their outcomes over the next 12 to 18 months will be the single most important factor in determining whether manufacturers choose to settle. If juries return substantial verdicts finding that Novo Nordisk and Eli Lilly failed to warn patients, settlement pressure will mount quickly.
For families navigating both dementia caregiving and a potential drug injury claim, the key takeaway is that waiting is the biggest risk. Statutes of limitations are running, medical records become harder to obtain with time, and memories — particularly those of witnesses and caregivers — fade. Even if the litigation itself takes years to resolve, establishing your claim now preserves your rights and positions your family to participate in any future resolution.
Conclusion
The Ozempic and GLP-1 litigation offers a real path to compensation for people who suffered serious gastrointestinal injuries — gastroparesis, bowel obstructions, gallbladder removal, and related harms — that they allege were not adequately warned about by drug manufacturers. For dementia patients and their families, the stakes are compounded by the difficulty of recognizing adverse drug reactions in cognitively impaired individuals and the urgency imposed by progressing illness. The lawsuits consolidated in MDL 3094 are moving forward, and the next phase of bellwether trials will set the tone for potential settlements.
If your family is in this situation, act now. Collect medical records, build a timeline of drug use and symptoms, and consult with a qualified mass tort attorney who can evaluate your specific circumstances. You do not need to pay anything upfront, and preserving your claim today keeps your options open regardless of how the litigation unfolds. The legal system moves slowly, but it cannot help those who never step through the door.
Frequently Asked Questions
Can I file a claim on behalf of a family member with dementia who cannot manage legal matters?
Yes. A legal guardian, someone with power of attorney, or a court-appointed representative can file a lawsuit on behalf of a person who is mentally incapacitated. The court process for establishing this authority varies by state, but it is routine in mass tort litigation involving elderly or cognitively impaired plaintiffs.
What if my loved one passed away after suffering side effects from Ozempic?
The estate or surviving family members may be able to file a wrongful death claim if the death is connected to injuries allegedly caused by the drug. An attorney can evaluate whether the medical evidence supports causation between the GLP-1 medication and the death.
Does it matter whether Ozempic was prescribed for diabetes or for weight loss?
For purposes of the lawsuit, both on-label (diabetes) and off-label (weight loss) use are relevant. Some attorneys argue that off-label prescribing actually strengthens the failure-to-warn claim because the risk-benefit calculus is different for weight management than for a serious metabolic disease.
How much compensation can I expect?
It is too early to project specific dollar amounts. Settlement values in pharmaceutical mass torts vary widely based on injury severity, and no settlement fund has been established yet in the GLP-1 MDL. Be cautious of any attorney or website that quotes specific figures at this stage.
Will filing a lawsuit affect my loved one’s Medicare or Medicaid benefits?
Lawsuit proceeds can potentially affect means-tested benefits like Medicaid and Supplemental Security Income. However, there are legal tools such as special needs trusts that can protect settlement funds without disqualifying a beneficiary. This is an important conversation to have with your attorney before any settlement is finalized.
